The University of Southampton
University of Southampton Institutional Repository

Banting Memorial lecture 2022: Type 2 diabetes and nonalcoholic fatty liver disease: partners in crime

Banting Memorial lecture 2022: Type 2 diabetes and nonalcoholic fatty liver disease: partners in crime
Banting Memorial lecture 2022: Type 2 diabetes and nonalcoholic fatty liver disease: partners in crime

Nonalcoholic fatty liver disease (NAFLD) was first described in the 1980s, but in the 21st century, NAFLD has become a very common condition. The explanation for this relatively recent problem is in large part due to the recent epidemic of obesity and type 2 diabetes (T2DM) increasing the risk of NAFLD. NAFLD is a silent condition that may not become manifest until severe liver damage (fibrosis or cirrhosis) has occurred. Consequently, NAFLD and its complications often remain undiagnosed. Research evidence shows that NAFLD is extremely common and some estimates suggest that it occurs in up to 70% of people with T2DM. In the last 5 years, it has become evident that NAFLD not only increases the risk of cirrhosis, primary liver cancer and end-stage liver disease, but NAFLD is also an important multisystem disease that has major implications beyond the liver. NAFLD increases the risk of incident T2DM, cardiovascular disease, chronic kidney disease and certain extra-hepatic cancers, and NAFLD and T2DM form part of a vicious spiral of worsening diseases, where one condition affects the other and vice versa. Diabetes markedly increases the risk of liver fibrosis and liver fibrosis is the most important risk factor for hepatocellular carcinoma. It is now possible to diagnose liver fibrosis with non-invasive tools and therefore it is important to have clear care pathways for the management of NAFLD in patients with T2DM. This review summarises key recent research that was discussed as part of the Banting lecture at the annual scientific conference in 2022.

0742-3071
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c

Byrne, Christopher (2022) Banting Memorial lecture 2022: Type 2 diabetes and nonalcoholic fatty liver disease: partners in crime. Diabetic Medicine, 39 (10). (doi:10.1111/dme.14912).

Record type: Review

Abstract


Nonalcoholic fatty liver disease (NAFLD) was first described in the 1980s, but in the 21st century, NAFLD has become a very common condition. The explanation for this relatively recent problem is in large part due to the recent epidemic of obesity and type 2 diabetes (T2DM) increasing the risk of NAFLD. NAFLD is a silent condition that may not become manifest until severe liver damage (fibrosis or cirrhosis) has occurred. Consequently, NAFLD and its complications often remain undiagnosed. Research evidence shows that NAFLD is extremely common and some estimates suggest that it occurs in up to 70% of people with T2DM. In the last 5 years, it has become evident that NAFLD not only increases the risk of cirrhosis, primary liver cancer and end-stage liver disease, but NAFLD is also an important multisystem disease that has major implications beyond the liver. NAFLD increases the risk of incident T2DM, cardiovascular disease, chronic kidney disease and certain extra-hepatic cancers, and NAFLD and T2DM form part of a vicious spiral of worsening diseases, where one condition affects the other and vice versa. Diabetes markedly increases the risk of liver fibrosis and liver fibrosis is the most important risk factor for hepatocellular carcinoma. It is now possible to diagnose liver fibrosis with non-invasive tools and therefore it is important to have clear care pathways for the management of NAFLD in patients with T2DM. This review summarises key recent research that was discussed as part of the Banting lecture at the annual scientific conference in 2022.

Text
Banting Review_accepted_clean - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (509kB)
Text
DUK-Banting Figures 1 & 2 final_submitted - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (134kB)
Text
Diabetic Medicine - 2022 - Byrne - Banting memorial lecture 2022 Type 2 diabetes and nonalcoholic fatty liver disease - Version of Record
Available under License Creative Commons Attribution.
Download (322kB)

More information

Accepted/In Press date: 30 June 2022
e-pub ahead of print date: 5 July 2022
Published date: 5 July 2022
Additional Information: Funding Information: CDB is supported in part by the Southampton National Institute for Health and Care Research (NIHR) Biomedical Research Centre (IS‐BRC‐20004), UK. Publisher Copyright: © 2022 The Author. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

Identifiers

Local EPrints ID: 468236
URI: http://eprints.soton.ac.uk/id/eprint/468236
ISSN: 0742-3071
PURE UUID: 7a9263e9-c387-4b46-bbf4-657f5152945d
ORCID for Christopher Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 08 Aug 2022 16:42
Last modified: 15 Sep 2022 01:36

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×